Routine three-drug antiretroviral prophylaxis — Competitive Intelligence Brief

Routine three-drug antiretroviral prophylaxis (Routine three-drug antiretroviral prophylaxis) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy Infectious Disease / Virology Small molecule

Target snapshot

Routine three-drug antiretroviral prophylaxis (Routine three-drug antiretroviral prophylaxis) — University of North Carolina, Chapel Hill. A combination of three antiretroviral drugs that work together to suppress HIV replication by targeting different stages of the viral lifecycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Routine three-drug antiretroviral prophylaxis TARGET	Routine three-drug antiretroviral prophylaxis	University of North Carolina, Chapel Hill	marketed	Antiretroviral combination therapy
Atripla or Stribild	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
TRUVADA + Raltegravir	TRUVADA + Raltegravir	Fenway Community Health	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase and HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Arm A: ABC+3TC+NNRTI	Arm A: ABC+3TC+NNRTI	Medical Research Council	marketed	Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Chang Gung Memorial Hospital · 1 drug in this class
3. Danish HIV Research Group · 1 drug in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
6. Kristine Patterson, MD · 1 drug in this class
7. PETHEMA Foundation · 1 drug in this class
8. University of Alberta · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class